NervGen Pharma Corp.
NGEN.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -79.64% | -3.94% | -14.70% | -25.71% | -6.38% |
| Total Depreciation and Amortization | -35.02% | -47.52% | -56.05% | -61.25% | -42.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 268.58% | -2.81% | -17.53% | -24.59% | -43.68% |
| Change in Net Operating Assets | -22.51% | 296.65% | 42.66% | 2.52% | 440.93% |
| Cash from Operations | -13.60% | -0.37% | -40.39% | -76.45% | -47.14% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.48% | 193.09% | 176.03% | 159.49% | 142.09% |
| Cash from Investing | 69.48% | 193.09% | 174.46% | 157.12% | 141.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 1.36% | -66.44% | -69.52% | -89.41% | 2,716.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.24% | 57.96% | 62.90% | 69.58% | -- |
| Cash from Financing | 1.39% | -68.38% | -71.28% | -91.64% | 2,861.01% |
| Foreign Exchange rate Adjustments | 243.86% | -5,020.45% | -234.26% | 26.98% | -139.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -20.21% | -245.63% | -199.91% | -225.28% | 154.49% |